Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AANAmerican Academy of Neurology
AChAcetylcholine
AChRAcetylcholine receptor
ADAAntidrug antibody
AEAdverse event
AHFSAmerican Hospital Formulary Service
ALTAlanine aminotransferase
ANAAntinuclear antibody
ASTAspartate aminotransferase
ATCAnatomical Therapeutic Chemical
CH50Total hemolytic complement activity
CHOChinese hamster ovary
CIConfidence interval
CIDPChronic inflammatory demyelinating polyneuropathy
CMAPCompound muscle action potential
CPIOCost per improved outcome
CTCAECommon Terminology Criteria for Adverse Events
CTISClinical Trials Information System
DILDrug-induced lupus
dsDNADouble-stranded DNA
EAMGExperimental autoimmune myasthenia gravis
EMGElectromyography
EOMGEarly-onset myasthenia gravis
EQ-5DEuroQol 5-dimension questionnaire
EQ-5D-5LEuroQol 5-dimension, 5-level questionnaire
evLYGEqual value of life-years gained
FACITFunctional Assessment of Chronic Illness Therapy
FcRnNeonatal Fc receptor
FDAU.S. Food and Drug Administration
FFSFee-for-service
FSSFatigue Severity Scale
GCGlucocorticoid
gMGGeneralized myasthenia gravis
HBPBHealth benefit price benchmark
HCRUHealthcare resource utilization
HRHazard ratio
HRQoLHealth-related quality of life
HUI3Health Utilities Index Mark 3
IC90Concentration producing 90% inhibition
IC95Concentration producing 95% inhibition
ICERIncremental cost-effectiveness ratio; Institute for Clinical and Economic Review
IgGImmunoglobulin G
INDInvestigational New Drug application
INNInternational nonproprietary name
ISImmunosuppressant
ISRInjection site reaction
IVIntravenous
IVIgIntravenous immunoglobulin
LOMGLate-onset myasthenia gravis
LOSLength of stay
LRP4Low-density lipoprotein receptor-related protein 4
MACMembrane attack complex
MADMultiple ascending dose
MedDRAMedical Dictionary for Regulatory Activities
MGMyasthenia gravis
MG-ADLMyasthenia Gravis Activities of Daily Living
MG-QoL-15rMyasthenia Gravis Quality of Life 15-item revised
MGCMyasthenia Gravis Composite
MGFAMyasthenia Gravis Foundation of America
MGTXThymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone
MMNMultifocal motor neuropathy
MMRMMixed model for repeated measures
MSEMinimal symptom expression
MTXMethotrexate
MuSKMuscle-specific kinase
NHSNational Health Service
NMANetwork meta-analysis
NMJNeuromuscular junction
NMOSDNeuromyelitis optica spectrum disorder
NNTNumber needed to treat
NSISTNonsteroidal immunosuppressive therapy
OLEOpen-label extension
OROdds ratio
PDPharmacodynamics
PISPostintervention status
PKPharmacokinetics
PLEXPlasma exchange
PPPMPer patient per month
PYPerson-years
Q2WEvery 2 weeks
Q4WEvery 4 weeks
QALYQuality-adjusted life-year
QMGQuantitative Myasthenia Gravis score
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
RNSRepetitive nerve stimulation
RRRate ratio
SADSingle ascending dose
SAESerious adverse event
SCSubcutaneous
SCIgSubcutaneous immunoglobulin
SDStandard deviation
SFEMGSingle-fiber electromyography
SLESystemic lupus erythematosus
SLRSystematic literature review
TEAETreatment-emergent adverse event
TPPTarget product profile
ULNUpper limit of normal
WHOWorld Health Organization
YTETyrosine, threonine, and glutamate substitutions in the Fc domain that extend half-life